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The observed homology between G-proteins which regulate adenylate cyclase and ras proteins and the sug- 
gested role of rcls in the regulation of adenylate cyclase in yeast prompted us to examine the regulation of 
adenylate cyclase in three cell lines: (i) NIH 3T3 cells, (ii) NIH 3T3 cells transformed by high levels of the 
normal rasH gene product and (iii) NIH 3T3 cells transformed by a mutated rasH gene product. We found 
that the regulation of adenylate cyclase by G-proteins is identical in the three cell lines, although the re- 
sponse of the transformed NIH 3T3 cells to agonists is strongly attenuated. Our data suggest hat mamma- 
lian ras products do not interact directly with adenylate cyclase, although their increased expression may 
indirectly inhibit the interactian of adenylate cyclase stimulatory receptors with G-proteins. 
ras gene 
1. INTRODUCTION 
Genes of the ru.s family are present in all eukary- 
otes, including humans and yeast [l-4]. Activated 
versions of these genes have been found in a wide 
variety of spontaneous human tumors, in tumors 
experimentally induced in animals by chemical car- 
cinogens or ionizing radiation, and in acute trans- 
forming retroviruses. These activated genes can in- 
duce celluiar transformation of mammalian cell 
lines in vitro, and retroviruses carrying these genes 
are highly oncogenic in viva. 
Previous studies indicated that cells transformed 
by the ras-containing Kirsten murine sarcoma 
virus have alterations in CAMP metabolism [5,6]. 
Recent studies indicate significant similarities be- 
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tween mammalian and yeast ras genes. ras genes 
from these species can function in the heterologous 
system [7,&l. In addition, mammalian and yeast 
US proteins share the capacity to bind guanine 
nucleotides and to hydrolyze GTP [9,10], Activa- 
tion of these genes via certain point mutations in 
their protein coding sequences is associated with 
decreased GTPase activity [l l-13]. 
The cellular targets of ras genes have not been 
defined. Significant sequence homology between 
rots proteins and regulatory G-proteins of the mam- 
malian adenylate cyclase system has been noted 
[14,15]. Recent observations in yeast suggest hat 
yeast ras can positively regulate adenylate cyclase 
activity in yeast [16,17]. To determine whether the 
mammalian ras genes have analogous effects on 
the mammalian adenylate cyclase complex, we 
have undertaken a series of experiments to study 
the effect of ras gene products on the cyclase 
system in mammalian cells. Our results strongly 
suggest that ras proteins do not directly affect 
adenylate cyclase activity in these cells. 
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2. MATERIALS AND METHODS 
The V-RAS cell line (clone 13-3-B4) has been 
described [18]. It was obtained by transforming 
NIH 3T3 cells with the H-l clone of Harvey 
murine sarcoma virus (Ha-MuSV), which encodes 
a mutated ras protein. This plasmid contains the 
circularly permuted full-length Ha-MuSV DNA 
[ 191. The c=RAS line was a mass culture of NIH 
3T3 cells transformed by a plasmid in which the 
normal rat c-Ha-ras-I gene with intervening se- 
quences was placed under the transcriptional con- 
trol of a retroviral long terminal repeat (LTR) by 
placing the ras gene downstream from the Ha- 
MuSV STR. This 13 kb plasmid was constructed 
by Dr B.M. Willumsen (University Microbiology 
Institute, Copenhagen, Denmark) by ligating 3 dif- 
ferent DNA fragments: (i) the 3.8 kb EcoRi/ 
&mHI fragment of pBR322, (ii) the 3.8 kb 
EcoRI/SstII fragment of clone H-l (this fragment 
of H-l contains the viral LTR but lacks all coding 
sequences of the viral v-ras gene), and (iii) the 5.4 
kb ~coRI~~~~H1 fragment of the normal genomic 
rat c-Ha-ras-f gene (&one pHLB [ZO]). Prior to 
ligation, the SstII end of the H-l fragment was 
made flush and converted to an &oRI end via ad- 
dition of an oligonucleotide linker. Following liga- 
tion of the 3 fragments, a clone (pBW192) in which 
the LTR was upstream from and in the same tran- 
scriptional orientation as the ras gene was iden- 
tified and selected. Clone pBW192 induces foci of 
transformed NIH 3T3 cells with about l/10 the ef- 
ficiency of the H-l clone (approx. 5 vs 5 x 10 foci 
per pg DNA). The foci induced by pBW 192 usually 
appear 2-3 days later than do those induced by 
H-1. 
Cholera toxin and pertussis toxin were obtained 
from List (CA). All other chemicals were obtained 
from Sigma, except for forskolin which was ob- 
tained from Calbiochem, and RO-20-1724 which 
was obtained from Hoffman-LaRoche (NJ). The 
methods used for each biochemical assay are given 
in the appropriate figure legend. 
3. RESULTS AND DISCUSSION 
The ras genes can be activated to induce mor- 
phological transformation of mammalian cells by 
two mechanisms: elevated expression of a normal 
ras protein or amino acid substitution in the ras 
protein [3,4]. We studied various parameters of 
adenylate cyclase activity on 3 different cell lines: 
(i) NIH 3T3 cells (wild type), (ii) NIH 3T3 cells 
transformed by high levels of the normal rat 
cellular (c) r@sH gene (GRAS cells), and (iii) NIH 
3T3 cells tr~sformed by Ha-MuSV, which ex- 
presses the mutant viral (v) rasH gene (v=RAS 
cells). Compared with the protein encoded by the 
normal C-~QS~ gene, v=rasH encodes a protein that 
contains two activating amino acid substitutions. 
Table I 
Effect of cholera toxin and of pertussis toxin on the 
adenylate cyclase 
% conversion of 13H]ATP to 
[3H]cAMP/h 
Toxin 3T3 {WT) c-RAS h=RAS 
Cholera toxin 15.2 k2.5 12.9 f 1.1 15.9 rtri.3 
Pertussis toxin 1.52t0.03 1.63kO.22 1.3 20.17 
Basal (IBMX) 0.311-0.07 0.36kO.08 0.32+0,10 
CeIfs were planted 24 h prior to each experiment in 
24-weI1 Costar dishes at a density of 2x 10’ ceIIsiweIf. 
They were grown in Dulbecco’s modified Eagles medium 
(DMEM) supplemented with 10% fetal calf serum. Prior 
to labelling with [3H]adenine (15-30 Ci/mmol, New 
England Nuclear) cells were washed twice with DMEM 
(2 ml/well) at 37°C and then incubated with 2 Cilwell 
[3H]adenine for 2 h. Maximal incorporation of i3H]- 
adenine into the ATP pool was achieved at 45 min (not 
shown). The wells were then washed 3 times with warm 
DMEM prior to the addition of the toxins. Then Zpg/ml 
(final concentration) of either cholera toxin (Schwartz- 
Mann) or pertussis toxin (List) was added to the medium 
and the medium su~pIemente~ with 0.5 mM (final con- 
centration) of the phospb~iesterase inhibitor R020-1724 
in a final volume of 0.5 ml/well. At different time points 
0.4 ml ice-cold 25% trichloroacetic acid was added 
immediately followed by 100 pl of a solution containing 
the following nucleotides (pH 7.4): adenine, adenosine, 
CAMP, AMP, ADP, and ATP at a final concentration 
of 0.5 mM. Then 3OUO-3500 cpm of [32P]cAMP (ICN, 
CA) were added to each well and the sample analyzed 
for [‘HIcAMP according to Salomon [25]. The 32P 
counts were used to calculate the extent of conversion of 
[3H]ATP into (‘H]cAMP. The total incorporation of 
[‘H]adenine into the [‘H]ATP pod was determined in 
each experiment. Accumulation of f3H]cAMP was linear 
up to over 2 h. Data shown are for a f h time point and 
are the average of 3 wells plus the standard error of the 
mean 
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The c-RAS cells contain about IO-times as much 
rasH protein as do the V-RAS cells; both lines grow 
in agar, but the V-RAS cells form agar colonies 
faster than c-RAS (not shown). 
These cell lines were used to study the possible 
interaction between ras proteins and the com- 
ponents of the hormonally regulated adenylate 
cyclase. The complex is composed of two classes of 
receptors: stimulatory (R,) and inhibitory (Ri), 
which interact with the catalytic unit (C) through 
a stimulatory G-protein (G,) [21] and an inhibitory 
protein (Gi) [22], respectively. We first examined 
the adenylate cyclase activity in response to agents 
which directly affect the G-protein system: cholera 
toxin, which activates C through ADP-ribosyl- 
ation of the G, [23] protein, and pertussis toxin, 
which activates C through ADP-ribosylation of the 
Gi protein [22,24]. Table 1 shows that the response 
of wild-type NIH3T3 and the two ras transformed 
cell lines to the bacterial toxins was almost iden- 
tical. These results suggest hat ras transformation 
does not directly affect the interactions between 
Fig.1. Response of 3T3 cells to PGE and forskolin. 
Assays were performed as described intable 1. Forskolin 
(Calbiochem) and PGEl (Sigma) when used were made 
as 0.1 M stock solutions in DMSO. Basal activity, 
RO-20-1724 (0.5 mM) only; Fo, 0.1 ,uM forskolin; PGEI 
(solid box), 1 pM, PGEr (dashed lined box), 1OOpM; Fo 
+ PGEr, 0.1 pM forskolin + 1 .OpM PGEr; FO, 1OOpM 
forskolin. Note that c-rus 3T3 cells respond better to 
PGEr than wild-type 3T3 cells. This is due to the fact 
that these cells desensitize much more slowly to PGEI 
than do wild-type 3T3 cells (not shown); therefore, the 
longer the incubation times the higher the discrepancy in 
favor of C-RAS 3T3 cells. There is no clue as yet to the 
Fig.2. Response of 3T3 cells to (- )-isoproterenol and 
forskolin. Assays were conducted as described in table 1. 
Isoproterenol had a maximal effect on the intact cells at 
1.0 pM and half-maximal effect at 30?6 nM. Isopro- 
terenol was used at 1 .O pM throughout. Fo, 0.1 PM for- 
skolin; IS0 + Fo, 1.0 M (-)-isoproterenol + 0.1 pM 
forskolin. Both wild-type 3T3 and C-RAS 3T3 cells 
origin of this phenomenon. undergo desensitization to isoproterenol. 
either Gi or G, with the catalytic subunit of 
adenylate cyclase. 
We then proceeded to examine the response of 
the adenylate cyclase in these cell lines to two 
stimulatory hormones: prostaglandin Ei (PGEi), 
and ( - )-isoproterenol, which activate adenylate 
cyclase through prostaglandin and &adrenergic 
receptors, respectively. In parallel we also analyzed 
the response of adenylate cyclase to the diterpene 
forskolin, which activates the catalytic unit of 
adenylate cyclase [26,27] but also synergizes with 
stimulatory hormones [28,29]. Examination of the 
response of the 3 cell lines to stimulatory hormones 
and forskolin revealed some differences. Fig.1 
shows that wild-type 3T3 and c-RAS 3T3 respond- 
ed well to PGEi whereas V-RAS 3T3 cells did not. 
The characteristic synergism between the stimula- 
tory agent and low forskolin concentrations, which 
is clearly seen in wild-type 3T3 and c-RAS 3T3, is 
absent from V-RAS 3T3. The blunted hormonal 
response in V-RAS cells probably reflects a lack of 
PGE, receptors in these cells [30]. Diminish ed 
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response to PGE has also been observed in other 
types of transformation [30-321, suggesting that 
this impaired response is not specific for ras 
transformed cells. 
Interestingly, the response of the V-RAS 3T3 
cells to ( - )-isoproterenol was somewhat different 
from their response to PGEr. Although V-RAS 3T3 
cells, unlike c-RAS 3T3 and wild-type 3T3, did not 
respond to (- )-isoproterenol, they did respond to 
isoproterenol plus forskolin (fig.2). This finding 
may indicate a deficient ability of G, to couple to 
the ,&adrenergic receptor in the V-RAS 3T3 cells 
whose response to this ligand has been restored by 
forskolin. We do not know what accounts for the 
lesion in the &receptor to G, coupling in V-RAS 
3T3 cells. Examination of the total number of /3- 
adrenergic receptors in the 3 cell types revealed 
that V-RAS 3T3 cells possess almost as many recep- 
tors as c-RAS cells, although both transformed cell 
Table 2 
Maximal “~1-cyanopindoiol binding sites in NIH 3T3, 
c-RAS/NIH 3T3 and h-RAS/NIH 3T3 
Cell type Maximal number of 
receptors 
37°C 22OC 
Wild-type NIH 3T3 8100 + 650 35000 f 1500 
c-RAS/NIH 3T3 1400 + 110 7800 f 600 
h-RAS/NIH 3T3 lOOOk 80 2650 + 200 
Cells were planted in 24-well dishes 24 h prior to the 
binding experiment as described in table 1. The serum- 
containing medium was removed and the celIs washed 
twice with DMEM medium. Then triphcate welis were 
incubated with 0.5 ml DMEM containing iZSI-cyano- 
pindolol (Amersham, 1950 Ci/mmol) in the concentra- 
tion range lo-300 pM in the absence and presence of 1.0 
M I-propranolol (ICI, England). Incubation was per- 
formed at 22 or 37°C for 2 h. The medium was subse- 
quently removed, the cells washed 3 times with 2.0 ml 
ice-cold Dulbecco’s PBS with Ca’+ and Mg’+, then 0.5 
ml of 0.5 N NaOH containing 0.1% Triton X-100 was 
added to each well. The well was scraped and the total 
volume removed for counting in an LKB gamma 
counter. Non-specific binding (S-15%) was subtracted 
and the data analyzed according to Scatchard using a 
computer program as described 1331. Binding curves 
were normal (non-cooperative) and the dissociation con- 
stant for ‘251-cyanopindoloI was found to be 33 f 4 pM 
at 23°C and 30+_3 pM at 37°C 
lines displayed many fewer receptors than the un- 
transformed NIH 3T3 cells (table 2). 
None of the 3 cell lines responded to cuz-adren- 
ergic agonists or adenosine Al agonists which in- 
duce adenylate cyclase inhibition (not shown). 
However, Gi is probably present in these cells, 
since treatment with islet-activating protein (IAP, 
pertussis toxin) induced a 4-5-fold activation of 
the basal adenylate cyclase activity in all 3 lines 
tested (table 1). 
In summary, our results are consistent with 
previous studies suggesting adecreased stimulation 
of adenylate cyclase activity in cells transformed 
by a variety of genes [30-321. Our analysis has ex- 
amined this system in detail for cells transformed 
by a rus proto-oncogene as well as for cells trans- 
formed by a mutated version of this gene. In con- 
trast to results obtained with the yeast adenylate 
cyclase system, ras proteins have not been found to 
be positive regulators of mammalian adenylate 
cyclase. Recent in vitro reconstitution experiments 
between mammalian adenylate cyclase and mam- 
malian ras proteins [34], which were published 
after we obtained the in vivo results reported here, 
also suggest hat there is no direct interaction be- 
tween T~.Y and mammalian adenylate cyclase. 
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